Peanut allergy vaccine is considered one of the best ways to protect infants against peanut allergies, as well as other types of allergies. This vaccine was specially designed for the prevention of peanut allergy and is currently being tested in individuals. Recent studies have shown that people who have had incidents of anaphylactic shock with an allergen in the past can be protected by this vaccine. Preliminary studies show promising results and indicate that this vaccine could very well become a major tool in the fight against allergies.
Growing prevalence of peanut allergy around the world is driving the growth of peanut allergy vaccine market. According to Food Allergy Research & Education, more than 170 foods have been reported to cause allergic reactions. Eight major food allergens – milk, egg, peanut, tree nuts, wheat, soy, fish, and shellfish – are responsible for most serious food allergic reactions in the United States. Peanut allergy incidences are more common in countries like UK, Australia and US
According to the American Academy of Allergy Asthma & Immunology, 30.4% of children with food allergies have suffered from multiple allergy attacks. Peanut allergy is such an epidemic disease in the United States that the Federal Food Allergen Labeling and Consumer Protection Act (FALCPA) has required that all packaged foods sold in the United States that contain peanuts as ingredient must display the word “peanut” prominently on the label. .
In February 2019, Aravax, an Australia-based biotechnology company, presented positive Phase I data for a clinical trial, evaluating the safety and tolerability of a new vaccine “PVX108” at the American Academy of Allergy, Asthma & Immunology (AAAAI). It is an intradermal immunotherapy vaccine against peanut allergy.In January 2020, the United States Food and Drug Administration approved Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp] to reduce allergic reactions, including anaphylaxis, which can occur with accidental exposure to peanutsIn December 2020, Aimmune Therapeutics, Inc., a Nestlé Health Science Company announced that the European Commission (EC) has approved PALFORZIA® [defatted powder of Arachis hypogaea L., semen (peanuts)] for the treatment of peanut allergyRequest a sample report here:https://www.coherentmarketinsights.com/insight/request-sample/121Main key players: Allergy Therapeutics, Zicam, Aravax, Immunomic Therapeutic, Inc., Astellas and Aimmune.Peanut Allergy Vaccine Market Segmentation
On the basis of end user, the global peanut allergy vaccine market is categorized into:
A government initiative to raise awareness and obtain regulatory approvals for peanut allergy vaccine is required for market growth. Some of the other methods of treating peanut allergy are oral immunotherapy and treatment with epinephrine. However, none of these treatments have gained traction in the peanut allergy treatment market.
Tailored information according to niche requirements:LIMITED TIME OFFER – Hurry!Exclusive offer !!! Buy the report at a reduced rate !!!Get discount for buyers UP TO 30% OFF On any research reportPurchase this full report on a company:
https://www.coherentMarketinsights.com/promo/buynow/121Note – In order to provide a more accurate market forecast, all of our reports will be updated prior to delivery taking into account the impact of COVID-19.(* If you have any special requirement, please let us know and we will offer the report as you want.)Contact:
Coherent Market Insights 1001 4th Ave, # 3200 Seattle, WA 98154, USA Email: [email protected] USA: + 1-206-701-6702